About Biomarkers Consortium
The Biomarkers Consortium brings together various partners to identify, develop and qualify potential biomarkers to improve drug development and regulatory decision-making
This exceptional group of organizations has aligned to further efforts dedicated to the discovery, development and the seeking of regulatory approval for biological markers (i.e. biomarkers) that support new drug development, preventive medicine and medical diagnostics.
Working to support research and guide clinical practice is the main goal of The Biomarkers Consortium. This collaborative effort ensures that the voice of all stakeholders involved in biomarker research is heard and contributes to strides made in support of promising initiatives undertaken by The Consortium in areas such as cancer, immunity & inflammation, metabolic disorders and neuroscience.
Become a part of the growing list of contributing members from industry, foundations, professional associations and patient advocacy organizations, working together along with our government colleagues from the National Institutes of Health and U.S. Food and Drug Administration to achieve a new era of predictive, preventive and personalized medicine through biomarker research.
The Biomarkers Consortium was established by the Foundation for the National Institutes of Health, the National Institutes of Health, the U.S. Food and Drug Administration and Pharmaceutical Research and Manufacturers of America. In addition, the Centers for Medicare & Medicaid Services and Biotechnology Industry Organization have been instrumental in the implementation and organization of The Biomarkers Consortium.
For more information about the policies and procedures of The Consortium, please contact us at firstname.lastname@example.org.
Publications about the Biomarkers Consortium:
- The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction. Menetski J, Hoffmann S, Cush S, Kamphaus T, Austin C, Herrling P, Wagner J. Clinical Pharmacology & Therapeutics Volume 105(4). 2019 April.
- The FNIH Biomarkers Consortium embraces the BEST. Menetski J, Austin C, Brady L, Eakin G, Leptak C, Meltzer A, Wagner J. Nature Reviews Drug Discovery. 2019, Feb.
American Society for Clinical Pharmacology & Therapeutics (ASCPT): "How To Develop and Qualify Biomarkers: Biomarker Consortium Perspective" Speaker: Joseph P. Menetski, Ph.D., Associate Vice President of Research Partnerships, FNIH
FNIH Biomarkers Consortium - Beta Cell Project "A New Tool for Diabetes Research"